FRA:ABL • US0028241000
ChartMill assigns a Buy % Consensus number of 80% to ABL.DE. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-07-23 | Raymond James | Maintains | Outperform |
| 2021-07-23 | Credit Suisse | Maintains | Outperform |
| 2021-07-23 | Morgan Stanley | Maintains | Overweight |
| 2021-07-20 | SVB Leerink | Maintains | Market Perform |
| 2021-07-12 | Wells Fargo | Maintains | Overweight |
| 2021-06-02 | BTIG | Maintains | Buy |
| 2021-06-02 | Barclays | Maintains | Overweight |
| 2021-06-02 | Wells Fargo | Maintains | Overweight |
| 2021-06-02 | Raymond James | Maintains | Outperform |
| 2021-06-02 | Credit Suisse | Maintains | Outperform |
| 2021-06-02 | Morgan Stanley | Maintains | Overweight |
| 2021-06-02 | Citigroup | Maintains | Buy |
| 2021-05-25 | Barclays | Initiate | Overweight |
| 2021-04-21 | Morgan Stanley | Maintains | Overweight |
| 2021-04-15 | Atlantic Equities | Initiate | Neutral |
| 2021-03-11 | Raymond James | Maintains | Outperform |
35 analysts have analysed ABL.DE and the average price target is 115.93 EUR. This implies a price increase of 21.97% is expected in the next year compared to the current price of 95.05.
The consensus rating for ABBOTT LABORATORIES (ABL.DE) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering ABBOTT LABORATORIES (ABL.DE) is 35.